Home > Maligne hematologie > Lymfoïde ziekten > Non-Hodgkin lymfomen (NHL) > Mantelcellymfoom (MCL) > Shine

Shine

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma

Deze print is 24 uur geldig na het aanmaken. Aangemaakt op: 29-5-2024, 0:28